L. Di Clemente

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
L Di Clemente, Laura Di Clemente
Publication record
17 papers · 716 citations · H-index 8

PAPERS

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.
20260 citationsauthor #23
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
20253 citationsauthor #45
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures
202511 citationsauthor #12
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)
20254 citationsauthor #62
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
202415 citationsauthor #7
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
202425 citationsauthor #15
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
20240 citationsauthor #15
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
20240 citationsauthor #7
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
202335 citationsauthor #10
The first report of the Italian Migraine Registry (I-GRAINE)
202213 citationsauthor #27
Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study
20211 citationsauthor #29
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study
20210 citationsauthor #9
Long-term (>48 weeks) safety and tolerability of erenumab in real-life
20210 citationsauthor #29
Postoperative treatment with phytotheraphy Graminex G63 (CERNILEN-Flogo®) after greenlight laser XPS (180W) photovaporization of the prostate (PVP), can affect patient's quality of life?
20201 citationsauthor #7
Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine.
2006293 citationsauthor #3
Nociceptive Blink Reflex and Visual Evoked Potential Habituations Are Correlated in Migraine
200593 citationsauthor #1
Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks.
2004220 citationsauthor #3

TIMELINE

2004 220 citations

2005 93 citations

2006 293 citations

2020 1 citations

2021 1 citations

2022 13 citations

2023 35 citations

2024 40 citations

2025 18 citations

2026 0 citations

L. Di Clemente

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT